Net Revenue (in thousands, unaudited) Three Months Ended March 31, 2023 Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Three Months Ended December 31, 2023 Twelve Months Ended December 31, 2023 Cardiopulmonary United States $ 39,609 $ 50,001 $ 89,610 $ 52,281 $ 141,891 $ 60,467 $ 202,358 Europe 36,385 39,339 75,724 35,484 111,208 46,206 157,414 Rest of World 59,750 64,773 124,523 61,190 185,713 58,627 244,340 135,744 154,113 289,857 148,955 438,812 165,300 604,112 Neuromodulation United States 94,489 104,065 198,554 102,475 301,029 106,464 407,493 Europe 13,280 15,125 28,405 12,661 41,066 16,369 57,435 Rest of World 12,954 13,991 26,945 13,744 40,689 14,093 54,782 120,723 133,181 253,904 128,880 382,784 136,926 519,710 Other Revenue 6,951 6,588 13,539 8,278 21,817 7,906 29,723 Totals United States 140,267 159,973 300,240 161,583 461,823 173,221 635,044 Europe 49,643 54,459 104,102 48,129 152,231 62,561 214,792 Rest of World 73,508 79,450 152,958 76,401 229,359 74,350 303,709 $ 263,418 $ 293,882 $ 557,300 $ 286,113 $ 843,413 $ 310,132 $ 1,153,545 Net Revenue (in thousands, unaudited) Three Months Ended March 31, 2022 Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Three Months Ended December 31, 2022 Twelve Months Ended December 31, 2022 Cardiopulmonary United States $ 41,264 $ 40,404 $ 81,668 $ 41,374 $ 123,042 $ 48,590 $ 171,632 Europe 32,670 33,684 66,354 28,871 95,225 33,320 128,545 Rest of World 46,990 54,828 101,818 53,812 155,630 58,391 214,021 120,924 128,916 249,840 124,057 373,897 140,301 514,198 Neuromodulation United States 87,210 91,431 178,641 96,504 275,145 99,397 374,542 Europe 12,456 13,710 26,166 11,130 37,296 12,995 50,291 Rest of World 10,561 12,654 23,215 14,201 37,416 14,744 52,160 110,227 117,795 228,022 121,835 349,857 127,136 476,993 Other Revenue 9,024 7,440 16,464 6,713 23,177 7,437 30,614 Totals United States 136,269 138,086 274,355 143,410 417,765 153,793 571,558 Europe 45,126 47,372 92,498 39,998 132,496 46,306 178,802 Rest of World 58,780 68,693 127,473 69,197 196,670 74,775 271,445 $ 240,175 $ 254,151 $ 494,326 $ 252,605 $ 746,931 $ 274,874 $ 1,021,805 Exhibit 99.2 LivaNova PLC Historical Recast of Segment Data Unaudited

Segment Income (Loss) (in thousands, unaudited) Three Months Ended March 31, 2023 Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Three Months Ended December 31, 2023 Twelve Months Ended December 31, 2023 Cardiopulmonary $ 9,174 $ 12,812 $ 21,986 $ (2,193) $ 19,794 $ 6,613 $ 26,407 Neuromodulation 27,006 38,148 65,154 41,930 107,084 46,300 153,384 Segment income 36,180 50,960 87,140 39,737 126,878 52,913 179,791 Other income/ (expense) (38,522) (33,584) (72,106) (35,279) (107,386) (140,903) (248,289) Operating (loss) income $ (2,342) $ 17,376 $ 15,034 $ 4,458 $ 19,492 $ (87,990) $ (68,498) Segment Income (Loss) (in thousands, unaudited) Three Months Ended March 31, 2022 Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Three Months Ended December 31, 2022 Twelve Months Ended December 31, 2022 Cardiopulmonary $ 8,549 $ 4,884 $ 13,433 $ (9,048) $ 4,385 $ 12,721 $ 17,106 Neuromodulation 37,478 51,360 88,838 43,281 132,119 40,656 172,775 Segment income 46,027 56,244 102,271 34,233 136,504 53,377 189,881 Other income/ (expense) (36,522) (24,488) (61,010) (166,206) (227,216) (39,417) (266,633) Operating income (loss) $ 9,505 $ 31,756 $ 41,261 $ (131,973) $ (90,712) $ 13,960 $ (76,752) Exhibit 99.2 LivaNova PLC Historical Recast of Segment Data Unaudited